Streetbeat News

Analyst Ratings

FUBO

Wedbush analyst Michael Pachter has reiterated an Outperform rating on FuboTV (NYSE:FUBO) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 12:48 pm

BOTZ

NVDA

ROBT

Morgan Stanley strategist Edward Stanley warns that Nvidia Corp.'s (NASDAQ:NVDA) surge of over 200% in 2023 could indicate the peak of the AI stock bubble. AI ETFs such as the Global X Robotics & Artificial Intelligence ETF (NASDAQ:BOTZ) and the First Trust Nasdaq Artificial Intelligence and Robotics ETF (NASDAQ:ROBT) have shown more modest returns, rising 33% and 23% respectively.

Portfolio Pulse from Piero Cingari

August 07, 2023 | 12:48 pm

XHR

Wells Fargo analyst Dori Kesten has maintained an Equal-Weight rating on Xenia Hotels & Resorts (NYSE:XHR) and lowered the price target from $14 to $13.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:47 pm

OPAD

Wedbush analyst Jay McCanless has maintained a Neutral rating on Offerpad Solutions (NYSE:OPAD) and lowered the price target from $7 to $5.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 12:47 pm

MAR

Wells Fargo analyst Dori Kesten maintains an Overweight rating on Marriott Intl (NASDAQ:MAR) and raises the price target from $212 to $222.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:46 pm

APLS

Wedbush analyst Laura Chico has maintained a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and lowered the price target from $32 to $29.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 12:46 pm

STAG

Wells Fargo analyst Blaine Heck has maintained an Equal-Weight rating on Stag Industrial (NYSE:STAG) and raised the price target from $33 to $37.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 12:45 pm

JAGX

Jaguar Health, Inc. (NASDAQ:JAGX) announced positive results from an independent pilot phase 2 study of crofelemer for the management of neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer. The study showed that crofelemer, Jaguar's FDA approved drug, may be effective for the management of neratinib-induced diarrhea. The results warrant further investigation of crofelemer for treatment of cancer therapy-related diarrhea (CTD). Top line results from the Company's ongoing phase 3 OnTarget clinical trial are expected in late October 2023.

Portfolio Pulse from Happy Mohamed

August 07, 2023 | 12:44 pm

TU

BMO Capital analyst Tim Casey has maintained an 'Outperform' rating on TELUS (TSX:T), but has lowered the price target from C$29 to C$27.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 12:42 pm

SRE

BMO Capital analyst James Thalacker has maintained a 'Market Perform' rating on Sempra Energy (NYSE:SRE) but lowered the price target from $168 to $160.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 12:41 pm